Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | ELANE | P08246 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13517020 | 1.00 | ATM (0.53) | ATML3MBTL1ELANETDP1ALOX15 | |
| SCHEMBL526417 | 0.94 | ATM (0.49) | ATML3MBTL1ELANETDP1ALOX15 | |
| SCHEMBL29169719 | 0.87 | ELANE (0.51) | ATML3MBTL1ELANETDP1ALOX15 | |
| SCHEMBL7943355 | 0.87 | ATM (0.56) | ATML3MBTL1ELANETDP1ALOX15 | |
| SCHEMBL27716432 | 0.87 | ATM (0.44) | ATML3MBTL1ELANETDP1ALOX15 | |
| SCHEMBL4191464 | 0.86 | ATM (0.58) | ATML3MBTL1ELANETDP1ALOX15 | |
| Guanidine SCHEMBL10882668 | 0.85 | ATM (0.42) | ATML3MBTL1ELANETDP1ALOX15 | |
| SCHEMBL27736207 | 0.84 | ELANE (0.49) | ATML3MBTL1ELANETDP1KDM4E | |
| SCHEMBL6554232 | 0.84 | ATM (0.52) | ATML3MBTL1ELANETDP1ALOX15 | |
| SCHEMBL31086956 | 0.83 | ATM (0.55) | ATML3MBTL1ELANETDP1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117402113-A | Production method of 8-hydroxyquinoline copper | 苏州华道生物药业股份有限公司 | 2024-01-16 | — | — | CN | claimed |
| CN-116082334-A | Preparation method of non-neridrone and intermediate thereof | 上海新礼泰药业有限公司 | 2023-05-09 | — | — | CN | claimed |
| CN-116041347-A | Preparation method of non-nereirenone intermediate | 上海新礼泰药业有限公司 | 2023-05-02 | — | — | CN | claimed |
| US-9447297-B2 | Phase change ink containing amorphous amides | XEROX CORPORATION (US) | 2016-09-20 | — | — | US | claimed |
| US-9193883-B2 | Phase change ink containing polyester for improved image robustness | XEROX CORPORATION (US) | 2015-11-24 | — | — | US | claimed |
| US-9127180-B2 | Phase change inks comprising organic pigments | XEROX CORPORATION (US) | 2015-09-08 | — | — | US | claimed |
| US-9090791-B2 | Mixtures of ester of tartaric acid and ester of citric acid as amorphous materials for phase change inks | XEROX CORPORATION (US) | 2015-07-28 | — | — | US | claimed |
| US-9051486-B2 | Phase change ink components and methods of making the same | XEROX CORPORATION (US) | 2015-06-09 | — | — | US | claimed |
| US-20150103122-A1 | Phase Change Ink Containing Amorphous Amides | XEROX CORPORATION (US) | 2015-04-16 | — | — | US | claimed |
| US-20140368588-A1 | Phase Change Ink Containing Polyester For Improved Image Robustness | Genesee Valley Innovations, LLC | 2014-12-18 | — | — | US | claimed |
| US-20130284051-A1 | PHASE CHANGE INKS COMPRISING FATTY ACIDS | XEROX CORPORATION (US) | 2013-10-31 | — | — | US | claimed |
| US-8465579-B2 | Solid ink compositions comprising crystalline esters of tartaric acid | XEROX CORPORATION (US) | 2013-06-18 | — | — | US | claimed |
| US-20120291663-A1 | PHASE CHANGE INK COMPONENTS AND METHODS OF MAKING THE SAME | XEROX CORPORATION (US) | 2012-11-22 | — | — | US | claimed |
| US-8308859-B1 | Phase change ink components and methods of making the same | XEROX CORPORATION (US) | 2012-11-13 | — | — | US | claimed |
| US-20120272860-A1 | PHASE CHANGE INK COMPONENTS AND METHODS OF MAKING THE SAME | XEROX CORPORATION (US) | 2012-11-01 | — | — | US | claimed |
| US-20120272863-A1 | SOLID INK COMPOSITIONS COMPRISING CRYSTALLINE ESTERS OF TARTARIC ACID | XEROX CORPORATION (US) | 2012-11-01 | — | — | US | claimed |
| CN-102757683-A | Solid ink compositions comprising amorphous esters of tartaric acid | XEROX CORP | 2012-10-31 | — | — | CN | claimed |
| CN-102757688-A | Phase change ink components and methods of making the same | XEROX CORP | 2012-10-31 | — | — | CN | claimed |
| EP-1109623-A1 | NOVEL SOLID OXIDATION CATALYSTS, IN PARTICULAR FOR EPOXIDATION OF PROCHIRAL COMPOUNDS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2001-06-27 | — | — | EP | claimed |
| WO-2000003802-A1 | NOVEL SOLID OXIDATION CATALYSTS, IN PARTICULAR FOR EPOXIDATION OF PROCHIRAL COMPOUNDS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2000-01-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120291663-A1 | PHASE CHANGE INK COMPONENTS AND METHODS OF MAKING THE SAME | ALK, TARDBP, MAPT | ATM 571/4885L3MBTL1 1318/4885ELANE 3020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.